Skip to main content

Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter

Written by Customer Service on . Posted in Public Companies.

CARLSBAD, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB) today announces FDA 510(k) clearance of the second-generation AcQMap® 3D imaging and mapping catheter which builds on its predecessor, improving handling and deliverability. This flagship 3D mapping and navigation catheter combines 48 ultrasound transducers responsible for creating the anatomical geometry and 48 engineered electrodes which enable electrical activation patterns to be displayed along the inner surface of the heart. Compatible with an 0.035” guidewire, the AcQMap catheter is designed to be inserted into the left and right atrium.
The AcQMap catheter is the cornerstone of Acutus’ innovative mapping platform. It is the world’s only integrated high-resolution ultrasound-based imaging and non-contact mapping catheter capable of capturing cardiac imaging information in addition to cardiac activation mapping.  This second-generation catheter carries additional benefits such as improved anatomy reconstruction, faster acquisition times and the potential for enhanced procedural efficiencies. The catheter also comes with a reusable and sterilizable cable that can be used up to 10 times, resulting in greater cost savings for health care systems.Customer feedback during development suggested that users perceived anatomy reconstruction to be faster than our generation one catheter*. Dr. Anil Rajendra from Grandview Medical Center in Birmingham, Alabama commented, “the new ergonomic handle and catheter deployment mechanism has the potential to allow me to maneuver the catheter with greater speed, ease and control.”The versatility of the AcQMap System allows physicians to map all types of atrial arrhythmias – simple and complex, spontaneous, repetitive and chaotic. The high definition maps provided by the AcQMap catheter allow physicians to identify ablation targets outside the pulmonary veins and strategically plan a patient-specific ablation strategy.  Physicians can efficiently map any arrythmia in under 3 minutes, ablate and then remap again to evaluate therapy effectiveness.*Acutus Medical data on file.About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias in each of its geographic markets. Founded in 2011, Acutus is based in Carlsbad, California.US Media Contacts
Levitate
(260) 408-5383
acutus@levitatenow.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.